VX-702

• Description :

  VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; p38 MAPK

• Type :

  Reference compound

• Related Pathways :

  Autophagy; MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/VX-702.html

• Purity :

  99.69

• Solubility :

  DMSO : ≥ 42 mg/mL

• Smiles :

  O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O

• Molecular Formula :

  C19H12F4N4O2

• Molecular Weight :

  404.32

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92 (6), 1387-1393.|[2]Braddock M, IDDB Meeting Report, 2005, March 14-15.|[3]Gill A, IDDB Meeing Report, 2002, March 06-08.|[4]Naka K, et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015 Aug 20;6:8039.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [745833-23-2]